For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Regulus Therapeutics Inc.

USPTO Granted Patents = 63

% Expired Patents = 38.1

CIPO Patents = 1

EPO Patents = 11

Forward Citations = 612

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

C Frank Bennett (27 out of 203 patents)

Balkrishen Bhat (27 out of 81 patents)

Susan M Freier (21 out of 263 patents)

4. Richard Holmes Griffey (21 out of 110 patents)

5. Eric G Marcusson (14 out of 31 patents)

6. Christine Esau (11 out of 14 patents)

7. B Nelson Chau (6 out of 6 patents)

8. Noga Yerushalmi (6 out of 10 patents)

9. Ravi Jain (6 out of 22 patents)

10. Ayelet Chajut (6 out of 8 patents)

11. Bridget Lollo (6 out of 6 patents)

12. Daniel J Hogan (4 out of 5 patents)

13. Jeremy Duffield (4 out of 6 patents)

14. Eric E Swayze (4 out of 206 patents)

15. Deidre A MacKenna (4 out of 7 patents)

Core Competencies:

MicroRNA

Polycystic Kidney Disease

Liver Cancer

Metabolic Disorders

Cellular Uptake

Oligomeric Compounds

Small Non-Coding RNAs

miR-122

miR-21

Fibrosis

Alport Syndrome

miR-155

63 patents: Sort by Forward Citations

1. 12559750 - Methods and Compositions for Treatment of Polycystic Kidney Disease (2026-02-24),

2. 12005120 - Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect (2024-06-11),

3. 11168325 - Methods for treatment of polycystic kidney disease (2021-11-09),

4. 10941400 - Compounds and methods for enhanced cellular uptake (2021-03-09),

5. 10633657 - Methods for treatment of polycystic kidney disease (2020-04-28),

6. 10584336 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2020-03-10),

7. 10301627 - Targeting microRNAs for the treatment of liver cancer (2019-05-28),

8. 10240151 - Compounds and methods for enhanced cellular uptake (2019-03-26),

9. 10150967 - MicroRNA compounds and methods for modulating miR-122 (2018-12-11),

10. 10138484 - Targeting microRNAs for metabolic disorders (2018-11-27),

11. 10093926 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2018-10-09),

12. 10072265 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2018-09-11),

13. 9994846 - MicroRNA compounds and methods for modulating miR-21 activity (2018-06-12),

14. 9994842 - Methods for use in modulating miR-122A (2018-06-12),

15. 9970011 - Methods for treatment of alport syndrome (2018-05-15),

Company Overview

Regulus Therapeutics Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development of microRNA therapeutics. The organization focuses on innovative treatments for various conditions, including polycystic kidney disease, liver cancer, and metabolic disorders. By leveraging its expertise in small non-coding RNAs and oligomeric compounds, Regulus aims to enhance cellular uptake and therapeutic efficacy, positioning itself at the forefront of RNA-based medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

63 Patents

#99 in San Diego, CA

#1,345 in California

#5,756 in US

#11,617 in the World

San Diego, CA, United States of America

Regulus Therapeutics Inc.

Forward Citations = 612

37 inventors:

C Frank Bennett (27 out of 203 patents)

Balkrishen Bhat (27 out of 81 patents)

Susan M Freier (21 out of 263 patents)

4. Richard Holmes Griffey (21 out of 110 patents)

5. Eric G Marcusson (14 out of 31 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Regulus Therapeutics Inc.. Retrieved from https://idiyas.com/company/regulus-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…